Solutions

• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery

OncoSolid™ Mesothelioma Cancer Organoid Model based CAR-T In Vitro Efficacy Assay Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Mesothelioma Organoid Models

Mesothelioma (MM) is commonly derived from mesothelium tissue of the lung and chest wall after exposure to crisis asbestos. Malignant mesothelioma is of low incidence, but heterogeneous and aggressive cancer. There is limited clinical treatment for MM with minimal effects. A sound preclinical model is critical to understand tumor biology and developing new therapeutic strategies. An organoid model is a 3D cell culture system that stands between 2D cell lines and in vivo animal models. Cancer organoids recapitulate the major alterations in molecular that mediate tumor cell resistance to clinical treatment. Furthermore, different types of cell components of tumors can be retained or introduced to organoid models to partially reproduce tumor microenvironment and hinder therapeutic drugs and cell migration. Cancer organoids are a popular preclinical tool for potential immunotherapy development and assessment.

Mesothelioma Organoid Establishment and Application Service at Creative Biolabs

Creative Biolabs provides a panel of well-characterized Malignant mesothelioma cancer organoid models that mirror the mutation characters and heterogeneity of human tumor tissues to predict the responses of CAR-based cell therapies.

Workflow

Fig.1 Schematic illustration of the main steps for mesothelioma cancer organoids production from mouse tumor tissue. (Gao, et al., 2022)

Subtypes of Organoids in Our Organoid Biobank

Complete Characterization of Colorectal Cancer Organoids

Advanced multi-omics techniques and accurate histopathological methods are used to analyze human patients' tissues and various pathway-derived cancer organoids.

Highlights

• Multiple passages and the long-term culture of organoids
• Screen therapeutic molecules in a high-throughput type
• Optimal culture medium to support organoids and T cell growth
• Validated highly efficient organoids generation protocol
• Reliable and reproducible experiment data

CAR-T Efficacy Test

The advanced preclinical cancer organoid models are useful to test the anti-tumor activity of promising immunotherapies in vitro.

• CAR-T and mock T cells are co-cultured with cancer organoids.
• Cancer organoids and T cells can be engineered or labeled with a fluorescent protein to facilitate observation by imaging.
• The organoid responses and T cell activities can both be monitored for evaluation.

Applications

Fig.2 Malignant mesothelioma cancer organoids are a useful tool for preclinical studies. (Gao, et al., 2022)

Related CAR-T Products and Services at Creative Biolabs

Creative Biolabs is committed to CAR-T therapy development using various advanced techniques and strategies. We have a library of CAR-cell therapy-related products that could be used for CAR-T production and efficacy test to get more information on lateral clinical responses.

If you're interested in our services, please contact us for a further consultant.

References

1. Guerra, E.; et al. Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics. Int. J. Mol. Sci. 2022, 23: 405.
2. Gao, Y.; et al. Organoids as a Model for Precision Medicine in Malignant Pleural Mesothelioma: Where Are We Today? Cancers. 2022, 14: 3758.